Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Guardant Health, Inc. - Common Stock (NQ:GH)

42.10 +1.48 (+3.64%)
Official Closing Price Updated: 4:15 PM EDT, Jun 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Guardant Health, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Guardant Health Announces $90.7 Million Registered Direct Offering with Baillie Gifford
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
From Guardant Health, Inc.
Via Business Wire
Blood-Based Colorectal Cancer CRC Screening Market Likely to Benefit From FDA's Panel Surprise Advisory Possibility: Analyst
Tuesday, Guardant Health Inc (NASDAQ: GH) announced that the FDA's Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee is tentatively scheduled to review the premarket... 
Via Benzinga
Exposures Product Safety
S&P 500, Nasdaq Set For Weaker Open As 'FOMO' Rally Cools: Analyst Says Only 'Black Swan Could Upset Santa's Sleigh' Now
Bond yields remain contained, providing a reason for traders to maintain their investments in stocks. 
Via Benzinga
Topics Stocks
Exposures US Equities
What 7 Analyst Ratings Have To Say About Guardant Health
Via Benzinga
7 Analysts Have This to Say About Guardant Health
Via Benzinga
Earnings Scheduled For November 6, 2023
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.16 per share on revenue of $366.82 million. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Guardant Health Announces Tentative Date of FDA Advisory Panel Review of Shield™ Blood Test
From Guardant Health, Inc.
Via Business Wire
Cancer Research UK and Guardant Health Launch Collaboration to Advance Cancer Research and Clinical Development Activities
From Guardant Health, Inc.
Via Business Wire
Guardant Health to present data at San Antonio Breast Cancer Symposium demonstrating utility of liquid biopsy in biomarker identification, therapy selection and residual disease detection
From Guardant Health, Inc.
Via Business Wire
The Latest Analyst Ratings for Guardant Health
Via Benzinga
Why Guardant Health Stock Popped Again Today
Wall Street loves this unprofitable biotech. 
Via The Motley Fool
Jim Cramer: Buy This Financial Stock, 'It's Up Substantially From Where It Was In The Spring'
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he remains a buyer of SoFi Technologies, Inc. (NASDAQ: SOFI). 
Via Benzinga
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Guardant Health, Inc.
Via Business Wire
Why Is Cancer Blood Test-Focused Guardant Health Stock Trading Lower Today?
Guardant Health Inc (NASDAQ: GH) shares are falling after the company announced it intends to appeal its verdict in the U.S. 
Via Benzinga
Guardant Health to Appeal Federal District Court Verdict
From Guardant Health, Inc.
Via Business Wire
Cancer Test Firm Guardant Health Posts Smaller Than Expected Q3 Loss, Lifts Annual Sales Outlook
Guardant Health Inc (NASDAQ: GH) reported Q3 revenue of $143 million, up 22% Y/Y, beating the consensus of $137.37 million 
Via Benzinga
Guardant Health Reports Third Quarter 2023 Financial Results and Increases Revenue Guidance
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Participate in Upcoming November Investor Conferences
From Guardant Health, Inc.
Via Business Wire
Guardant Health, Flatiron Health Announce Integration of Guardant Genomic Profiling Tests Into OncoEMR® Platform
From Guardant Health, Inc.
Via Business Wire
Bull Of The Day: NeoGenomics
NeoGenomics is a small-cap provider of cancer genetics diagnostics. They boast one of the most comprehensive oncology-focused testing menus in the world to help physicians diagnose and treat cancer. 
Via Talk Markets
First results from PEGASUS trial reported at ESMO show promise for use of liquid biopsy to guide adjuvant treatment of colon cancer
From Guardant Health, Inc.
Via Business Wire
Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030
EQNX::TICKER_START (OTCQB:TDSGF),(TSXV:TELO),(NASDAQ:GH),(NASDAQ:NTRA),(NYSE:DGX),(NASDAQ:NEO) EQNX::TICKER_END 
Via FinancialNewsMedia
Guardant Health to Report Third Quarter 2023 Financial Results on November 6, 2023
From Guardant Health, Inc.
Via Business Wire
1 Beaten-Down Healthcare Stock to Buy and Hold For 10 Years
This company's fight against a deadly disease could pay off. 
Via The Motley Fool
Which Is the Better Cancer-Testing Healthcare Stock: Exact Sciences or Guardant Health?
The oncology diagnostic companies are looking for better solutions in early cancer diagnosis. 
Via The Motley Fool
Why Guardant Health Stock Jumped 15% This Week
The precision oncology leader benefited from a pair of positive analyst notes this week. Here's what investors need to know. 
Via The Motley Fool
Guardant Health Has 'Underlying Business Strength' Says This Bullish Analyst
Shares of Guardant Health Inc (NASDAQ: GH) climbed during the premarket trading session and morning on Wednesday. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 28, 2023
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.